Elevated Heart Rate in Cardiovascular Diseases: A Target for Treatment?

Progress in Cardiovascular Diseases

Volumn 52, Issue 1, 2009, Pages 46-60

  Palatini, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Beta blockers; Calcium antagonists; Heart rate; Ivabradine; Tachycardia

Indexed keywords

AMIODARONE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLONIDINE; DIGOXIN; DILTIAZEM; DOCOSAHEXAENOIC ACID; FISH OIL; GUANABENZ; GUANFACINE; IVABRADINE; METHYLDOPA; METOPROLOL; MOXONIDINE; NEBIVOLOL; PINDOLOL; PLACEBO; PRACTOLOL; PROPRANOLOL; RILMENIDINE; TRANDOLAPRIL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG TARGETING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEART WORK; HUMAN; HYPERTENSION; IMPOTENCE; NONHUMAN; OXYGEN CONSUMPTION; QT PROLONGATION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK FACTOR; SOMNOLENCE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; TACHYCARDIA;

EID: 67650118795     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2009.05.005     Document Type: Article

References (137)

1. Levine H.J. Rest heart rate and life expectancy. J Am Coll Cardiol 30 (1997) 1104-1106
2. Azbel M.Y. Universal biological scaling and mortality. Proc Natl Acad Sci U S A 91 (1994) 12453-12457
3. Palatini P., and Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 11 S 1 (1997) 19-27
4. Palatini P., and Julius S. Review article: heart rate and the cardiovascular risk. J Hypertens 15 (1997) 3-17
5. Fox K., Borer J.S., Camm A.J., et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 50 (2007) 823-830
6. Cook S., Togni M., Schaub M.C., et al. High heart rate: a cardiovascular risk factor?. Eur Heart J 27 (2006) 2387-2393
7. Reil J.C., and Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 96 (2007) 585-592
8. Deibert D.C., and DeFronzo R.A. Epinephrine-induced insulin resistance in man. J Clin Invest 65 (1980) 717-721
9. Zeman R.J., Ludemann R., Easton T.G., et al. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta-2-receptor agonist. Am J Physiol 254 (1988) E726-E732
10. Jamerson K.A., Julius S., Gudbrandsson T., et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21 (1993) 618-623
11. Kaplan J.R., Manuck S.B., and Clarkson T.B. The influence of heart rate on coronary artery atherosclerosis. J Cardiovasc Pharmacol 10 suppl 2 (1987) S100-S102
12. Kaplan J.R., Manuck S.B., and Adams M.R. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 76 (1987) 1364-1372
13. Bassiouny H.S., Zarins C.K., Kadowaki M.H., et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 19 (1994) 426-434
14. Sutton-Tyrrell K., Alcorn H.G., Herzog H., et al. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 26 (1995) 1319-1324
15. Giannoglou G.D., Chatzizisis Y.S., Zamboulis C., et al. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol 126 (2008) 302-312
16. Chatzizisis Y.S., Coskun A.U., Jonas M., et al. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 49 (2007) 2379-2393
17. Palatini P. Heart rate as a cardiovascular risk factor. Eur Heart J 1 Suppl. B (1999) B3-B9
18. Gordon D., Guyton J., and Karnovsky N. Intimal alterations in rat aorta induced by stressful stimuli. Lab Invest 45 (1983) 14-19
19. Palatini P. Exercise haemodynamics in the normotensive and the hypertensive subject. Clin Sci 87 (1994) 275-287
20. Albaladejo P., Asmar R., Safar M., et al. Association between 24-hour ambulatory heart rate and arterial stiffness. J Hum Hypertens 14 (2000) 137-141
21. Sa Cunha R., Pannier B., Benetos A., et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 15 (1997) 1423-1430
22. Benetos A., Adamopoulos C., Bureau J.M., et al. Determinants of accelerated progression of arterial stiffness in normotensive and treated hypertensive subjects over a 6-year period. Circulation 105 (2002) 1202-1207
23. Mangoni A.A., Mircoli L., Giannattasio C., et al. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 14 (1996) 897-901
24. Tanaka N., Nozawa T., Yasumura Y., et al. Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol 40 (1990) 503-521
25. Sambuceti G., Marzilli M., Marraccini P., et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation 95 (1997) 2652-2659
26. Perski A., Olsson G., Landou C., et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 123 (1992) 609-616
27. Huikuri H.V. Heart rate dynamics as a marker of vulnerability to atrial fibrillation. J Cardiovasc Electrophysiol 19 (2008) 913-914
28. Heidland U.E., and Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104 (2001) 1477-1482
29. Palatini P., Casiglia E., Julius S., et al. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159 (1999) 585-592
30. Kannel W.B., Kannel C., Paffenbarger Jr. R.S., et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113 (1987) 1489-1494
31. Jouven X., Empana J.P., Schwartz P.J., et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 352 (2005) 1951-1958
32. Coburn A.F., Grey R.M., and Rivera S.M. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A/J mouse. Johns Hopkins Med J 128 (1971) 169-193
33. Beere P.A., Glagov S., and Zarins C.K. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226 (1984) 180-182
34. Albaladejo P., Carusi A., Apartian A., et al. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res 40 (2003) 320-328
35. Paffenbarger Jr. R.S., Hyde R.T., and Wing A.L. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 314 (1986) 605-613
36. Thompson P.D., Buchner D., Piña I.L., et al. AHA scientific statement. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. Circulation 107 (2003) 3109-3116
37. Leon A.S., Franklin B.A., Costa F., et al. AHA scientific statement. Cardiac rehabilitation and secondary prevention of coronary heart disease. Circulation 111 (2005) 369-376
38. Genovesi S., Zaccaria D., Rossi E., et al. Effects of exercise training on heart rate and QT interval in healthy young individuals: are there gender differences?. Europace 9 (2007) 55-60
39. Narkiewicz K., Maraglino G., Biasion T., et al. Interactive effect of cigarettes and coffee on daytime systolic blood pressure in patients with mild essential hypertension. J Hypertens 13 (1995) 965-970
40. Maron B.J. Structural features of the athlete heart as defined by echocardiography. J Am Coll Cardiol 7 (1986) 190-203
41. Palatini P., Visentin P., Dorigatti F., et al. Regular physical activity prevents development of left ventricular hypertrophy in hypertension. Eur Heart J 30 (2009) 225-232
42. Higashi Y., Sasaki S., Kurisu S., et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation 100 (1999) 1194-1202
43. Cornelissen V.A., and Fagard R.H. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension 46 (2005) 667-675
44. Grimm Jr. R.H., Grandits G.A., Cutler J.A., et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 157 (1997) 638-648
45. Christensen J.H., Korup E., Aarøe J., et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 79 (1997) 1670-1673
46. Mozaffarian D., Geelen A., Brouwer I.A., et al. Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112 (2005) 1945-1952
47. O'Keefe Jr. J.H., Abuissa H., Sastre A., et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 97 (2006) 1127-1130
48. Dallongeville J., Yarnell J., Ducimetiere P., et al. Fish consumption is associated with lower heart rates. Circulation 108 (2003) 820-825
49. Harris W.S., Kris-Etherton P.M., and Harris K.A. Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep 10 (2008) 503-509
50. Mori T.A., and Woodman R.J. The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9 (2006) 95-104
51. Peoples G.E., McLennan P.L., Howe P.R., et al. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol 52 (2008) 540-547
52. Teo K.K., Yusuf S., and Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 270 (1993) 1589-1595
53. Kjekshus J.K. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57 (1986) 43F-49F
54. The Goteborg Metoprolol Trial in acute myocardial infarction. Am J Cardiol 53 (1986) 10D-50D
55. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 310 (1984) 9-15
56. Taylor S.H., Silke B., Ebbutt A., et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 307 (1982) 1293-1301
57. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol 66 (1990) 779-785
58. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319 (1988) 385-392
59. Alderman M.H., Cohen H., Rogué R., et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 349 (1997) 594-598
60. Andersen L.T., Sigurd B., and Hansen J.F. Verapamil and circadian variation of sudden cardiac death. Am Heart J 131 (1996) 409-410
61. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 28 (2007) 3012-3019
62. Task Force of the European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 18 (1997) 394-413
63. Gibbons R.J., Chatterjee K., Daley J., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Available at:. http://www.acc.org/qualityandscience/clinical/guidelines/stable/update_index.htm Accessed May 3, 2006
64. van der Vring J.A., Daniels M.C., Holwerda N.J., et al. Combination of calcium channel blockers and β-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Br J Clin Pharmacol 47 (1999) 493-498
65. Stone P.H., Gibson R.S., Glasser S.P., et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group. Circulation 82 (1990) 1962-1972
66. Guth B.D., Heusch G., Seitelberger R., et al. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 60 (1987) 738-746
67. Simonsen S., Ihlen H., and Kjekshus J.K. Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. Acta Med Scand 213 (1983) 393-398
68. Di Francesco D., and Camm J.A. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64 (2004) 1757-1765
69. Di Francesco D. The contribution of the 'pacemaker' current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 434 (1991) 23-40
70. Monnet X., Ghaleb B., Colin P., et al. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther 299 (2001) 1133-1139
71. Borer J.S., Fox K., Jaillon P., et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107 (2003) 817-823
72. Tardif J.C., Ponikowski P., Kahan T., et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30 (2009) 540-548
73. Prasad U.K., Gray D., and Purcell H. Review of the I(f) selective channel inhibitor ivabradine in the treatment of chronic stable angina. Adv Ther 26 (2009) 127-137
74. Vilaine J.P., Bidouard J.P., Lesage L., et al. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol 42 (2003) 688-696
75. Guth B.D., Heusch G., Steitelberger R., et al. Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis. Circulation 75 (1987) 661-669
76. Fox K., Ford I., Steg P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008) 807-816
77. Fox K., Ford I., Steg P.G., et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372 (2008) 817-821
78. Lechat P., Packer M., Chalon S., et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double blind, placebo controlled, randomized trials. Circulation 98 (1998) 1184-1191
79. Packer M., Antonopoulos G.V., Berlin J.A., et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 141 (2001) 899-907
80. BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001) 1659-1667
81. CIBIS Investigators. A randomised trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90 (1994) 1765-1773
82. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 353 (1999) 9-13
83. Lechat P., Hulot J., Escolano S., et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 103 (2001) 1428-1433
84. Willenheimer R., van Veldhuisen D., Silke B., et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomised Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112 (2005) 2426-2435
85. Poole-Wilson P., Swedberg K., Cleland J., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
86. Packer M., Coats A., Fowler M., and and Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med 344 (2001) 1651-1658
87. MERIT Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
88. Flather M., Shibata M., Coats A., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
89. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
90. Swedberg K., Cleland J., Dargie H., et al., and Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
91. Krum H. Sympathetic activation and the role of beta-blockers in chronic heart failure. Aust N Z J Med 29 (1999) 418-427
92. Wikstrand J., Hjalmarson A., Waagstein F., et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 40 (2002) 491-498
93. Thackray S.D., Wright G.A., Witte K.K., et al. The effect of ventricular pacing on measurements of left ventricular function: a comparison between echocardiographic methods and with radionuclide ventriculography. Eur J Echocardiogr 7 (2006) 284-292
94. Flannery G., Gehrig-Mills R., Billah B., et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101 (2008) 865-869
95. De Ferrari G.M., Mazzuero A., Agnesina L., et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 10 (2008) 550-555
96. Böhm M., and Reil J.C. Perspectives of I(f) inhibition by ivabradine in cardiology. Drugs 67 Suppl 2 (2007) 43-49
97. Nul D.R., Doval H.C., Grancelli H.O., et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 29 (1997) 1199-1205
98. Gillman M.W., Kannel W.B., Belanger A., et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 125 (1993) 1148-1154
99. Benetos A., Rudnichi A., Thomas F., et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 33 (1999) 44-52
100. Thomas F., Rudnichi A., Bacri A.M., et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 37 (2001) 1256-1261
101. Palatini P., Thijs L., Staessen J., et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Int Med 162 (2002) 2313-2321
102. Kolloch R., Legler U.F., Champion A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 29 (2008) 1327-1334
103. King D.E., Everett C.J., Mainous III A.G., et al. Long-term prognostic value of resting heart rate in subjects with prehypertension. Am J Hypertens 19 (2006) 796-800
104. Palatini P., Dorigatti F., Zaetta V., et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 24 (2006) 1873-1880
105. Farinaro E., Stranges S., Guglielmucci G., et al. Heart rate as a risk factor in hypertensive individuals. The Italian Tensiopulse Study. Nutr Metab Cardiovasc Dis 9 (1999) 196-202
106. Palatini P., Longo D., Zaetta V., et al. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens 24 (2006) 1375-1381
107. Julius S., Krause L., Schork N.J., et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 9 (1991) 77-84
108. MRC working party: Medical Research Council trial of treatment of hypertension in older adults: principal results 304:405-12, 1992.
109. Collins R., Peto R., Mac Mahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335 (1990) 827-838
110. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
111. Khan N., and McAlister F.A. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 174 (2006) 1737-1742
112. Lindholm L.H., Carlberg B., and Samuelsson O. Beta blockers in primary hypertension: do age and type of beta-blocker matter?. J Hypertens 24 (2006) 2143-2145
113. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J 109 (1985) 1192-1198
114. Lithell H., Pollare T., and Vessby B. Metabolic effects of pindolol and propanolol in a double-blind crossover study in hypertensive patients. Blood Press 1 (1992) 92-101
115. Pischon T., and Sharma A.M. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2 (2001) 275-280
116. Bangalore S., Parkar S., Grossman E., et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100 (2007) 1254-1262
117. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 (2006) 1213-1225
118. Bangalore S., and Messerli F.H. Beta-blockers as fourth-line therapy for hypertension: stay the course. Int J Clin Pract 62 (2008) 1643-1646
119. Bangalore S., Messerli F.H., Kostis J.B., et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 50 (2007) 563-572
120. Bangalore S., Sawnehy S., and Messerli F.H. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 52 (2008) 1482-1489
121. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292 (2004) 2227-2236
122. Celik T., Iyisoy A., Kursaklioglu H., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 24 (2006) 591-596
123. Grassi G., Trevano F.Q., Facchini A., et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press 2 (2003) 35-40
124. Stadler P., Leonardi L., Riesen W., et al. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 42 (1987) 85-92
125. Suter P.M., and Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens Suppl 13 (1995) S11-S17
126. Kailasam M.T., Parmer R.J., Cervenka J.H., et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 26 (1995) 143-149
127. Lefrandt J.D., Heitmann J., Sevre K., et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. Am J Hypertens 14 (2001) 1083-1089
128. Palatini P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality-the effect of antihypertensive drugs. Drugs 57 (1999) 713-724
129. Messerli F.H., Hansen J.F., Gibson R.S., et al. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens 19 (2001) 977-982
130. Clozel J., Ertel E.A., and Ertel S.I. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens 15 suppl 5 (1997) S17-S25
131. Van Zwieten P.A. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens 15 suppl 1 (1997) S3-S8
132. Sica D.A. Centrally acting antihypertensive agents: an update. J Clin Hypertens 9 (2007) 399-405
133. Rosen P., Ohly P., and Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 15 suppl 1 (1997) S31-S38
134. Jouven X., Empana J.P., Escolano S., et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 103 (2009) 279-283
135. Palatini P., Benetos A., Grassi G., et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 24 (2006) 603-610
136. Vogel C.U., Wolpert C., and Wehling M. How to measure heart rate?. Eur J Clin Pharmacol 60 (2004) 461-466
137. Mancia G., Parati G., Pomidossi G., et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 9 (1987) 209-215